Glycosylated modified primate lentivirus envelope polypeptides

US6908617B1 · kind B1 · utility

Assignees

• DANA-FARBER CANCER INSTITUTE, INC. · US
• The Trustees of Columbia University in the City of New York · US

Inventors

• Richard Wyatt · Village of La Jolla, US
• Joseph Sodroski · Medford, US
• Peter Kwong · Washington, US
• Wayne A. Hendrickson · Dobbs Ferry, US

Key dates

• Filing date: Nov 10, 1998
• Grant date: Jun 21, 2005
• Expiry date: Nov 10, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16122
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

A modified polypeptide corresponding to an envelope glycoprotein of a primate lentivirus is described. The polypeptide has been modified from the wild-type structure so that it has at least two of the glycosylation sites proximal to the CD4 binding site or chemokine receptor site altered so that the alteration prevents glycosylation at that site or where glycosylation sites distal to these sites have been derivatized with a molecular adjuvant, while retaining the overall 3-dimensional structure of a discontinuous conserved epitope of the wild-type protein. Preferably, the polypeptide has both changes. Preferably, the primate lentivirus is HIV, and the protein is HIV-1 gp 120.